SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (NASDAQ: NSTR), a medical device company developing therapies for the treatment of neurological diseases and disorders, today announced an updated timeline related to data analysis of its EVEREST pivotal trial for stroke motor recovery and its planned PMA submission. After recent communications with the FDA, the Company now expects to unblind EVEREST data and announce four-week primary endpoint results in January 2008, and to submit its pre-market approval application, or PMA, including 24-week secondary endpoint data and other outcome measures, early in the second quarter of 2008.
